With broad and consolidated experience, Celidonio and Migliori is your partner to strengthen your ideas. With global reach, we can help protect your innovation and provide strategic from distinctive perspectives involving your Intellectual Property portfolio, advice on patents, trademarks, designs, and IP matters. Together we can face the challenges of the transforming world and be the agents of creation.
Brazilian Center for Research – CNPEM
CNPEM is a sophisticated and ebullient environment for research and development that is the only one of its kind in Brazil and found in only a few scientific centers in the world. The Center private, non-profit organization overseen by the Ministry of Science, Technology, and Innovation (MCTI). The Center is home to Sirius, the most complex project in Brazilian science and one of the world’s most advanced synchrotron light sources. CNPEM comprises highly specialized multi-thematic teams, globally competitive lab infrastructure that is open to the scientific community, strategic lines of research, innovative projects in partnerships with the productive sector, and training programs for researchers and students. CNPEM is an environment driven by research into solutions that impact the areas of health, energy and renewable materials, agro environmental and engineering. | The Brazilian Center for Research in Energy and Materials (CNPEM) is home to a state-of-the-art, multi-user and multidisciplinary scientific environment. A social organization overseen by the Ministry of Science, Technology and Innovation, CNPEM powers Brazil’s science with cutting-edge labs like Sirius, tackling global challenges in health, renewable materials, energy & sustainability.
Brazilian Pavilion
ABIQUIFI Abiquifi (Brazilian Industry Association of Active Pharmaceutical Ingredient) was founded in 1983 to represent and defend the pharmaceutical and API industry. At the beginning of 2010, it also represented companies engaged in the production of pharmaceutical adjuvants, non-active pharmaceutical inputs, and service providers in the sector. The main objective of Abiquifi is to stimulate production, technological development, and exports of active pharmaceutical ingredients manufactured in Brazil. Given the nature of the provider of the drug segment, the entity brings together the various links in this chain, promoting internationalization, research and development actions, and working with the sanitary control and promotion agencies. Brazilian Pharma & Health The Brazilian Pharma & Health Project is an initiative coordinated by the Brazilian Industry Association of Active Pharmaceutical Ingredient (Abiquifi) with the support of the Brazilian Trade and Investment Promotion Agency (ApexBrasil), that aims to expand the participation of companies from Brazilian pharmaceutical and APIs productive chain into the international scenario, seeking to increase exports, technology transfer, investment attraction and the internationalization of the sector. It promotes actions in business intelligence, international marketing, prospective missions, international fairs, business rounds, and trade missions directed to different target markets, including countries from all five continents. | Abiquifi (Brazilian Industry Association of Active Pharmaceutical Ingredient) was founded in 1983 to represent and defend the pharmaceutical and API industry. At the beginning of 2010, it also represented companies engaged in the production of pharmaceutical adjuvants, non-active pharmaceutical inputs, and service providers in the sector. The main objective of Abiquifi is to stimulate production, technological development, and exports of active pharmaceutical ingredients manufactured in Brazil. Given the nature of the provider of the drug segment, the entity brings together the various links in this chain, promoting internationalization, research and development actions, and working with the sanitary control and promotion agencies.
Blau Farmacêutica S.A.
Blau is a multinational leading company, a pioneer in developing Biotech medicines in Brazil, with more than 35 years of innovation and technology. Equipped with cutting-edge technology to produce Active Pharmaceutical Ingredients (APIs), with global operations (Americas, Europe and EUA) and export to more than 20 countries.
BLANVER FARMOQUIMICA E FARMACEUTICA S.A.
Blanver is a Brazilian pharmaceutical company with over 40 years of experience and global presence. We develop, license, and commercialize high-quality medicines and APIs for the Latin American market.
Biotimize
Biotimize is a Brazilian CDMO that provides personalized biotechnology and bioprocess engineering-based services for preclinical and clinical studies to global biopharmaceutical companies. Being the main driver of new regulatory models that value innovation, Biotimize works to develop new approaches to create a scenario where it is possible to democratize access to science and healing and create a positive impact on people. Our services (Mammalian cells, Bacteria, Yeast, Virus) – Cell Line Development – Process Development and Optimization – Bioproduction – Analytics Development – Technical- Economic Analysis – PoC material production – Preclinical material production – Clinical material production
BIONOVIS SA – COMPANHIA BRASILEIRA DE BIOTECNOLOGIA FARMACEUTICA
Bionovis is a Brazilian pharmaceutical biotechnology company whose objective is to promote the research & development, manufacturing, distribution, and commercialization of highly complex biopharmaceuticals. We constantly invest in highly qualified human resources and in the acquisition of equipment and technology. This structure allows us to fully produce several innovative biological, biosimilar and biopharmaceutical medicines for the treatment of various pathologies, increasing access to high-technology medicines for patients. In more than a decade of operation, we have built partnerships with major global leaders in the biopharmaceutical sector. Through these partnerships, we receive the complete technology to produce innovative biopharmaceuticals and biosimilars. In our history, we have already positively impacted around 1 million patients, through the provision of more than 16 million vials and syringes of biopharmaceuticals. We are committed to ensuring Brazil’s self-sufficiency in the development and manufacturing of high-quality, highly complex biological products, increasingly expanding the access of Brazilians to these medicines. Aligned with global standards and requirements required of the National Health Surveillance Agency – ANVISA (approved in November 2023 – API and December 2024 – Fill and Finish), regulatory agencies in the United States (Food and Drug Administration – FDA – expected for 2027) and Europe (European Medicines Agency – EMA – expected for 2027). Bionovis is looking for opportunities to license biological and biosimilar products for the Brazilian market and offers C(D)MO capabilities for Brazil and Latin America.
Bayer Brasil
Bayer is a global enterprise with core competencies in the life science fields of healthcare and agriculture. We design our products and services to help tackle some of the world’s biggest challenges, and to serve the most essential human needs of health and nutrition. At Bayer, we’re committed to driving sustainable development and generating a positive impact with our businesses. Through the power of science, we’re pioneering new possibilities that advance life. That means reimagining how we care for ourselves and one another by empowering everyday health, improving approaches to patient care, and finding better ways to nourish communities around the world.